Dr. Michael Charles Heinrich, MD

Dr. Heinrich practices at OHSU Hospital in Portland, Oregon, part of State of Oregon.

Dr. Heinrich's NPI, 1548278005, was assigned on August 3, 2006. Dr. Heinrich graduated from Johns Hopkins University School of Medicine in 1984. Dr. Heinrich holds Oregon license MD14573.

Dr. Heinrich's primary practice is OHSU Hospital, at 3181 SW Sam Jackson Park Road, Portland, OR 97239 in Multnomah County. The practice phone is (503) 494-9000.

Dr. Heinrich's primary practice is OHSU Hospital in Portland, Oregon, part of State of Oregon. The medical group on file is Oregon Health & Science University (OHSU). Dmand AI also links Dr. Heinrich to 1 more clinical lab, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heinrich practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Heinrich's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Heinrich is licensed in Oregon.

CMS data shows 550 Medicare services from Dr. Heinrich across 4 procedure codes in 2024, for 95 Medicare patients. Medicare paid $35,580 for them.

CMS counts 95 Medicare patients who saw Dr. Heinrich in 2024. The largest group is 65 to 74, with 47 patients. 57% of them have high cholesterol, and 55% have high blood pressure. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heinrich's median patient age at 71, with 49% women.

In 2024, Dr. Heinrich wrote 466 Medicare Part D claims for 55 patients. 76% of them were for generic drugs. CMS names the drug for 356 of them, across 13 drugs with 11 or more claims each, at $1,609,724 in total drug cost. In 2023, CMS named 353 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Heinrich for performance year 2024, reported through an alternative payment model (APM). Dr. Heinrich accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Heinrich as offering telehealth.

Dmand AI links 132 papers to Dr. Heinrich, published from 2003 to 2025. 2021 was the busiest year, with 14. The most frequent topics are Gastrointestinal Stromal Tumors, Proto-Oncogene Proteins c-kit and Protein Kinase Inhibitors. Dr. Heinrich has published most often in Clin Cancer Res. Dr. Heinrich's most frequent co-authors are George D. Demetri, MD, Neeta Somaiah, MD and Ping Chi, MD, PhD.

Dmand AI links Dr. Heinrich to 8 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase and Myeloproliferative Disorders. Novartis Pharmaceuticals sponsors the most, 2.

CMS Open Payments shows 48 general payments to Dr. Heinrich from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Novartis Pharmaceuticals Corporation paid the most, $19,123. It also lists 9 research payments totaling $4,722 from 2017 to 2025.

Dr. Heinrich graduated from Johns Hopkins University School of Medicine in 1984.